Pfizer Drops Danuglipron After GI Side Effects and Liver Risk

Rahul Somvanshi

Pfizer discontinued the drug Danuglipron after a patient developed potential drug-induced liver injury (DILI).

Photo Source: James Heilman, MD (CC  BY SA 3.0)

Representative Image.

The termination adds to Pfizer's growing list of obesity treatment failures. It is a long list.

Photo Source: Thiruthonti (CC-BY-SA-4.0)

Representative Image.

"While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients," said Dr. Chris Boshoff.

Photo Source: Tibor Végh (CC-BY-SA-3.0)

Representative Image.

The injectables dominating the market are Zepbound and Novo Nordisk

Photo Source: SharonDawn (CC-BY-SA-4.00)

Representative Image.

After the discontinuation, Eli Lilly shares rose 2.6% and Novo Nordisk increased by 3%. 

Photo Source: Argonne National Laboratory (CC BY-SA 2.0)

Representative Image.

BMO Capital Markets analyst Evan Seigerman stated the discontinuation sends Pfizer "back to the starting block

Photo Source: Pxhere

Representative Image.

It is important to develop oral medication for obesity as it will increase the effectiveness.

Photo Source: Pxhere

Representative Image.

Pfizer aims to reveal danuglipron data at future scientific conferences or in peer-reviewed journals. This information proves to be invaluable for oral weight loss drug development.

Photo Source: Dorota Badowska (CC BY-SA 3.0 IGO)

Representative Image.